PRE-TREATMENT IP-10 LEVELS AND IL28B GENOTYPE IN PREDICTION OF SVR IN PRIOR TREATMENT-EXPERIENCED GENOTYPE 1 HCV PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/ RIBAVIRIN IN THE REALIZE STUDY

被引：2
|
作者：
Vijgen, L. [1 ]
Talloen, W. [2 ]
Scholliers, A. [1 ]
Johansson, S. [1 ]
Tuefferd, M. [2 ]
De Meyer, S. [1 ]
Witek, J. [3 ]
Fanning, G. [1 ]
Picchio, G. [3 ]
Pol, S. [4 ,5 ]
Zeuzem, S. [6 ]
Aerssens, J. [1 ]
机构：
[1] Tibotec BVBA, Beerse, Belgium
[2] Janssen Res & Dev, Beerse, Belgium
[3] Janssen Res & Dev LLC, Titusville, NJ USA
[4] Univ Paris 05, INSERM, U1016, Paris, France
[5] Cochin Hosp, Assistance Publ Hop Paris, Paris, France
[6] Goethe Univ Frankfurt, Med Ctr, Frankfurt, Germany
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61179-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1167
引用
收藏
页码：S462 / S462
页数：1
相关论文
共 50 条
  • [21] CORRELATION OF IL28B POLYMORPHISM WITH DEGREE OF FIBROSIS: ANALYSIS OF TREATMENT-NAIVE AND TREATMENT-EXPERIENCED CAUCASIAN PATIENTS INFECTED WITH HCV GENOTYPE 1 IN THE GEN-C STUDY
    Mangia, A.
    de Ledinghen, V.
    Keiss, J.
    Valantinas, J.
    Brahm, J.
    Rasmann, N.
    Messinger, D.
    Tatsch, F.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S354 - S354
  • [22] MODELING PREDICTS CLINICALLY MEANINGFUL SVR RATES IN GENOTYPE 1 TREATMENT-EXPERIENCED PATIENTS BASED ON RESULTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS TREATED WITH SOFOSBUVIR plus PEGINTERFERON plus RIBAVIRIN FOR 12 WEEKS
    Muir, A.
    Nelson, D. R.
    Gordon, S. C.
    Feld, J. J.
    Patel, K.
    Lawitz, E.
    Sheikh, A. M.
    Brainard, D. M.
    Symonds, W. T.
    McHutchison, J. G.
    Bekele, B. N.
    Mangia, A.
    Gane, E. J.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S495 - S495
  • [23] Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study
    Berg, Thomas
    Andreone, Pietro
    Pol, Stanislas
    Roberts, Stuart
    Younossi, Zobair
    Diago, Moises
    Lawitz, Eric J.
    Focaccia, Roberto
    Foster, Graham R.
    Horban, Andrzej
    Lonjon-Domanec, Isabelle
    DeMasi, Ralph
    Picchio, Gaston
    Luo, Donghan
    De Meyer, Sandra
    Zeuzem, Stefan
    LIVER INTERNATIONAL, 2015, 35 (02) : 448 - 454
  • [24] The association of IL28B genotype with peginterferon-α/ribavirin ( PR) treatment outcome and liver interferon-stimulated gene (ISG) expression is determined by HCV genotype
    Holmes, Jacinta A.
    Congiu, Mario
    Bonanazinga, Sara
    Sandhu, Manjeet K.
    Kia, Yin H.
    Bell, Sally
    Visvanathan, Kumar
    Sievert, William
    Bowden, Scott
    Desmond, Paul V.
    Thompson, Alexander J.
    HEPATOLOGY, 2012, 56 : 1042A - 1043A
  • [25] IMPACT OF IL28B GENOTYPE ON VIROLOGIC RESPONSE IN PRIOR TREATMENT FAILURE PATIENTS WHO RECEIVED MK-7009 IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN
    Mobashery, N.
    Wong, P.
    Zhang, S.
    Bhanja, S.
    Warner, A.
    Shaw, P. M.
    Rodriguez-Torres, M.
    Gane, E. J.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S467 - S467
  • [26] IL28B genotype analysis in HCV treatment experienced patients in a large French Nationwide prospective multicentric study: ILIADE Study
    Bourliere, Marc
    Renou, Christophe
    Ouzan, Denis
    Asselah, Tarik
    Allegre, Thierry
    Cadranel, Jean Francois D.
    Delasalle, Patrick
    Haddad, Nabil
    Lafeuillade, Alain
    Penaranda, Guillaume
    Pinta, Alexandrina
    Khiri, Hacene
    Halfon, Philippe
    HEPATOLOGY, 2012, 56 : 1026A - 1026A
  • [27] EARLY VIROLOGICAL RESPONSE PROFILES WITH TELAPREVIR (T) IN COMBINATION WITH PEGINTERFERON-ALFA-2A (P) AND RIBAVIRIN (R) IN GENOTYPE 1 HCV TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS ARE SIMILAR
    Poordad, F.
    McHutchison, J. G.
    Shiffman, M. L.
    Berg, T.
    Muir, A. J.
    Manns, M. P.
    Di Bisceglie, A. M.
    Terrault, N.
    Picchio, G.
    Kwong, A.
    Bengtsson, L.
    George, S.
    Adda, N.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S121 - S122
  • [28] IMPACT OF IL28B GENOTYPE (GT) ON SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS (PTS) WHO REQUIRE PEGINTERFERON (PEG) AND/OR RIBAVIRIN (R) DOSE MODIFICATION (DM) DURING HCV TREATMENT
    Shiffman, Mitchell L.
    Poordad, F. Fred
    Reddy, Rajender
    Afdhal, Nezam H.
    Brown, Robert S.
    Flamm, Steven L.
    Harrison, Stephen A.
    Noviello, Stephanie
    Brass, Clifford A.
    Pedicone, Lisa
    Albrecht, Janice K.
    Sulkowski, Mark S.
    HEPATOLOGY, 2011, 54 : 999A - 999A
  • [29] LOW RATES OF SVR TO PEGINTERFERON PLUS RIBAVIRIN IN HCV GENOTYPE 1 IL28B RS12979860 CC CIRRHOTIC PATIENTS WITHOUT RAPID VIROLOGICAL RESPONSE
    Degasperi, E.
    Aghemo, A.
    Galmozzi, E.
    Valenti, L.
    Rumi, M. G.
    De Francesco, R.
    De Nicola, S.
    Soffredini, R.
    Colombo, M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S425 - S425
  • [30] IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naive and treatment-experienced patients other than prior partial- and null-responders
    Calisti, Giorgio
    Tavares, Amanda
    Macartney, Malcolm J.
    McCormick, Adele
    Labbett, Wendy
    Jacobs, Michael
    Dusheiko, Geoffrey
    Rosenberg, William M.
    Haque, Tanzina
    SPRINGERPLUS, 2015, 4
12345